Overview

A Phase I Trial of Bortezomib and Sunitinib

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side effects.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborators:

Millennium Pharmaceuticals, Inc.
Pfizer

Treatments:

Bortezomib
Sunitinib